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Background: Immunoglobulin (Ig) E is well-known to play a critical role in allergic diseases. We investigated the
association between longitudinal change in total IgE level and the asthma control in patients with adult asthma.
Methods: For this retrospective study, 154 patients with asthma aged 21–82 years were recruited from the
allergy and pulmonary units of the Showa University Hospital. Data on longitudinal changes in IgE over the
preceding 10 years were collected and logarithmically transformed. Associations between longitudinal change in
IgE and clinical characteristics including asthma control test (ACT) score, asthma control, pulmonary function test,
and antigen specific IgE, were assessed.
Results: Patients with increased IgE tended to have significantly higher mean age, more episodes of acute
exacerbation within a year, lower ACT scores, and used oral corticosteroids more frequently than those with
decreased or unchanged IgE. The prevalence of uncontrolled asthma was higher in patients with increased IgE
than in those with decreased or unchanged IgE. Mean %FEV1 and FEV1% were lower in patients with increased
IgE than in those with decreased or unchanged IgE. Moreover, the prevalence of Aspergillus-specific IgE was
higher in patients with increased IgE than in those with decreased or unchanged IgE.
Conclusions: These data suggest that a longitudinal increase in total IgE is associated with both poor asthma
control and Aspergillus-specific IgE in patients with adult asthma.
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Immnoglobulin E (IgE), the fifth and last immuno-
globulin to be identified, was first reported in 1966 [1].
Measurements of total and antigen-specific IgE are
helpful for diagnosing allergic diseases. IgE is a critical
factor for the development of bronchial hyperrespon-
siveness in asthmatics [2]. Epidemiological studies have
shown that total IgE level is higher in patients with
asthma, particularly in children, than in non-asthmatics
[3-5]. Recently, a longitudinal analysis of European* Correspondence: tanakaa@med.showa-u.ac.jp
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unless otherwise stated.Community Respiratory Health Survey data showed
that total IgE was associated with new-onset asthma
among atopics [6]. Meanwhile, the association between
total IgE level and non-atopic asthma remains contro-
versial [7,8].
Total IgE level is higher in children with severe asthma
than in those with mild to moderate asthma [9]. In The
Epidemiology and Natural History of Asthma: Outcomes
and Treatment Regimens study, an association between
a high level of total IgE and asthma severity was ob-
served among younger subjects with difficult-to-treat or
severe asthma [10,11]. In a study conducted by de
Marco et al., a high level of IgE was a strong predictor
of moderate-to-severe asthma among 856 European
adult patients with asthma [12]. However, recent globalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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search Program [13] and the European Network For Un-
derstanding Mechanisms of Severe Asthma [14], showed
no correlation between asthma severity and levels of
total and antigen-specific IgE, raising suspicion that IgE
may not play a role in the deterioration of asthma con-
trol in patients with adult asthma. In recent years, a re-
combinant humanized monoclonal anti-IgE antibody,
omalizumab, has been used in patients with allergic se-
vere asthma [15,16]. Its effectiveness reminds us of the
functional importance of IgE in severe asthma.
In general, serum total IgE concentration seems to
peak in early adolescence and decrease with age [17-19].
However, longitudinal change in IgE is heterogeneous
among patients with adult asthma. Although there have
been several large-scale cross-sectional studies of total
IgE and antigen-specific IgE [20,21], only one multicen-
ter study has assessed longitudinal change in total IgE
and prevalence of IgE sensitization in the same popula-
tion [22]. This study showed an overall decrease in total
IgE over 10 years, in line with previous cross-sectional
studies [17-19]. Meanwhile, few studies have interpreted
longitudinal change in total IgE in individuals.
The aim of the present study was to investigate the
association between longitudinal change in total IgE
and asthma control to elucidate the role of longitudinal
change in IgE in patients with asthma.
Methods
Study design
This was a retrospective study conducted in the allergy
and pulmonary units of the Showa University Hospital,
Tokyo, Japan, between January 2011 and December
2012. The study protocol was approved by the Showa
University ethics committee and written informed con-
sent was obtained.
Study subjects
Out of 854 asthmatic patients, we recruited 154 pa-
tients, whose longitudinal changes in total IgE in the
preceding 10 (±2) years could be obtained. All patients
had been regularly followed at Showa University Hos-
pital. Individuals with chronic obstructive pulmonary
disease (COPD) or other lung disease, smoking history
greater than 20 pack-years, being treated with omalizu-
mab, vocal cord dysfunction, or neurological disease
were excluded. No participants, even those who had
high IgE level, had parasitic infections. Asthma was di-
agnosed based on cough, breathlessness or dyspnea,
and demonstration of airflow variability. The latter was
determined according to a reversible airflow limitation
that represented an increase in forced expiratory vol-
ume in 1 s (FEV1) of 12% or 200 mL after the inhal-
ation of salbutamol.Data collection
Baseline data including medical history, Asthma Control
Test (ACT) score, spirometry, fractional exhaled nitric
oxide (FeNO), percent peripheral eosinophils, total and
specific IgE [Dermatophagoides pteronissinus (house
dust mite: HDM), Cryptomeria japonica (cedar), Ambro-
sia artemisiifolia (ragweed), Candida albicans (candida),
Aspergillus fumigatus (aspergillus), Alternaria alternata
(alternaria), dog dander, cat dander, Bombyx mori (moth),
and Blatta orientalis (cockroach)] were collected at enroll-
ment. The definition of atopic type was being positive to
crude house dust-specific IgE.
Asthma control was assessed using the validated Japa-
nese version of the ACT. Patients were subjectively eval-
uated for the degree of impairment caused by their
asthma during the preceding 4 weeks by responding to
five questions using a five-point scale.
Spirometry was performed using an AS-302 spirom-
eter (Minato Medical Science Co., Ltd., Osaka, Japan)
in accordance with American Thoracic Society/European
Respiratory Society guidelines [23,24] to determine FEV1,
forced vital capacity (FVC), and FEV1/FVC (FEV1%). The
highest value from three technically satisfactory attempts
was recorded. FEV1 and FVC values were expressed as a
percentage of the predicted value.
FeNO was measured by a portable device (NIOX
MINO, Aerocrine AB, Solna, Sweden) at an expiratory
flow rate of 50 mL/s for 10 s.
Serum total IgE levels, measured with a fluorescent en-
zyme immunoassay (ImmunoCAP-FEIA, Phadia, Freiburg,
Germany) were transformed logarithmically to normalize
their distribution. A zero was replaced with a value
half of the lowest value observed before log transform-
ation. Antigen-specific IgE was also measured with
ImmunoCAP-FEIA, and levels higher than class 2
were considered as positive. The longitudinal change
in total IgE (ΔIgE) was calculated as log total IgE at
present – log total IgE 10 years ago. An increase or
decrease in total IgE was arbitrarily designated as a
variation of >0.15 log10 kU/L.Statistical analyses
Results were expressed as mean ± SD for continuous
variables. FeNO values were transformed logarithmic-
ally to normalize their distribution. All analyses were
performed using JMP version 10 (SAS Institute Inc.,
Cary, NC, USA). Differences in the continuous variables
between groups were tested by analysis of variance
(ANOVA); if the differences between groups were sig-
nificant, comparisons were made by unpaired t-test.
Categorical variables were analyzed with χ2 tests. A











Figure 1 Distribution of the longitudinal change in IgE across
0.25 in patients with adult asthma.
Tanaka et al. Respiratory Research 2014, 15:144 Page 3 of 8
http://respiratory-research.com/content/15/1/144Results
Background
One hundred and fifty-four patients with asthma with
a median age of 62.5 years (range 21–82) were in-
cluded. The mean BMI was 23.1 ± 3.6, and 62 patients
(40.3%) were men. Thirteen patients (8.4%) were current
smokers, and 31 patients (20.1%) were ex-smokers at
the time of enrollment. The mean ACT score and
FeNO were 20.7 ± 3.7 and 51.3 ± 42.9 ppb, respectively.
In the pulmonary function test, the mean FVC andTable 1 Subject demographics and patient characteristics
Decrease (N = 63)
Age (years) 61.3 ± 14.6*
Gender (M/F) 27/36
BMI 23.7 ± 0.4
Adult onset, n (%) 45 (71.4)
Smoking status, never/ex/current (%) 46/12/5 (73.0/19.1/7.9)
Atopic type, n (%) 42 (66.6)
Pet owner, n (%) 16 (25.4)
Allergic rhinitis, n (%) 30 (47.6)
Pollinosis, n (%) 27 (42.8)
Treatment with higher than Step 4, (%)¶ 17 (26.9)
OCS on demand, none/rare/frequent (%) ‖ 35/22/6 (55.6/34.9/9.5)
Episode of acute exacerbation within a year 15 (23.8)
Eosinophils, % of WBC 5.45 ± 0.48
Pre-IgE, IU/L 1020.6 ± 1654.8
Pre-IgE (log-transforn), IU/L 2.59 ± 0.08***
FeNO, ppb 52.2 ± 5.6
Values are Mean ± SDs or medians (%).
†p values given for the ANOVA.
‡p values given for the Pearson χ2 test.
*p < 0.05 or **p < 0.01 or ***p < 0.001 versus increase.
¶ Treatment step is based on the Global Initiative for Asthma (GINA) guideline.
‖ none: never, rare: less than once a month, frequent: once or more a month.
OCS: oral corticosteroids.FEV1 were 2.5 ± 0.9 L (%FVC: 88.2 ± 19.3%), and 1.8 ±
0.8 L (%FEV1: 75.0 ± 23.0%), respectively.
Mean total IgE was 2.43 ± 0.65 log10 kU/L 10 years
ago and 2.37 ± 0.66 log10 kU/L at the time of the study.
An increase or decrease in IgE was arbitrarily designated as
a variation of >0.15 log10kU/L. Figure 1 displays the distri-
bution of patients according to longitudinal change in IgE.
Demographic details for the patient population are
shown in Table 1. No significant differences were ob-
served in gender, BMI, percent adult onset, smoking
status, atopic type, pet ownership, allergic rhinitis, pollino-
sis, eosinophils, or FeNO between the groups. However,
there were significant differences in age, prevalence of pa-
tients treated at levels higher than Step 4, frequency of use
of on-demand oral corticosteroid (OCS), episode of acute
exacerbation within a year, and pre-IgE level between the
groups. Mean age was significantly higher for patients
with increased IgE than for those with decreased or un-
changed IgE. However, in this study, there was no signifi-
cant correlation between ΔIgE and age (data not shown).
Mean pre-IgE level was significantly lower in patients with
increased IgE than in patients with decreased IgE.
ACT
To identify patients with poor asthma control, several
tools can be used globally, one of which is ACT. This
test comprises five questions to assess activity limitation,No change (N = 50) Increase (N = 41) p value
59.5 ± 13.7** 67.8 ± 11.2 0.011†
21/29 14/27 NS
23.2 ± 0.5 22.1 ± 0.5 NS
39 (78.0) 34 (82.9) NS
38/8/4/ (76.0/16.0/8.0) 26/11/4/ (63.4/26.8/9.8) NS
30 (60.0) 21 (51.2) NS
11(22.0) 9 (21.9) NS
23 (46.0) 15 (36.5) NS
24 (48.0) 21 (51.2) NS
14 (28.0) 20 (48.78) 0.045‡
40/8/2 (80.0/16.0/4.0) 23/12/6 (56.1/29.3/14.6) 0.046‡
7 (14.0) 15 (36.6) 0.042‡
4.75 ± 0.54 5.49 ± 0.60 NS
873.5 ± 2018.3 695.8 ± 2555.9 -
2.40 ± 0.09 2.22 ± 0.10 0.014†
50.7 ± 6.3 50.5 ± 7.0 NS















Figure 2 ACT scores of patients with asthma. Mean ACT scores
are shown on the top of the bars. ACT comprises five questions to
assess activity limitation, shortness of breath, nighttime symptoms,
use of rescue medication, and patient’s overall rating of asthma
control over the previous 4 weeks. *: Significant difference (P <0.01)
versus the unchanged IgE group, as determined by t-test following
a one-way analysis of variance (ANOVA).
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medication, and the patient’s overall rating of asthma
control over the previous 4 weeks. Mean ACT score
was significantly lower for patients with increased IgE
(Figure 2, P =0.006) and for patients with decreased IgE
(Figure 2, P =0.007) than for patients with no change in
IgE.
Control level
The Global Initiative for Asthma (GINA) guidelines,
the most widely used asthma guidelines in the world,
emphasize the importance of evaluating asthma control
rather than asthma severity. The GINA guidelines pro-
vide a categorical scale for assessing asthma control,Figure 3 Distribution of patients according to asthma control level. A
based on the categorical scale of Global Initiative for Asthma. Low data we
between the groups (P =0.014).consisting of well-controlled, partly controlled, or uncon-
trolled asthma [25]. Asthma control levels of the patients
in this study are shown in Figure 3. Significant differences
were observed between the groups (P =0.014). In particu-
lar, 34.1% of the patients with increased IgE had uncon-
trolled asthma, compared with 12.7% and 10.0% of
patients with decreased and unchanged IgE, respectively.
Pulmonary function test
Lung function, as an assessment of variable airway ob-
struction, is an objective of asthma control. There was
no significant difference in %FVC between the groups
(Figure 4A). In contrast, significant differences were ob-
served in %FEV1 and FEV1%. The patients with in-
creased IgE had lower %FEV1 than did the patients
with no change in IgE (Figure 4B, P =0.006), and lower
FEV1% than patients with decreased or unchanged IgE
(Figure 4C, P <0.001).
IgE specific to inhaled antigens
The prevalence of IgE specific to inhaled antigens is
shown in Table 2. There was no significant difference
between the three groups for HDM, cedar, ragweed, can-
dida, alternaria, dog dander, cat dander, moth, and cock-
roach. In contrast, a significant difference was found for
aspergillus (P <0.001). The patients with increased IgE
had a higher prevalence of aspergillus sensitization than
other groups. In addition, patients who were positive to
aspergillus-specific IgE had higher ΔIgE than patients
who were negative for aspergillus-specific IgE (0.123 ±
0.36 vs −0.098 ± 0.41, P =0.008).
Discussion
In the present study, we found that patients with a lon-
gitudinal increase in total IgE used on-demand OCSsthma was identified as controlled, partly controlled or uncontrolled
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Figure 4 Pulmonary function tests in patients with asthma.
%FVC (A), %FEV1 (B), and FEV1% (C) are shown. The highest value from
three technically satisfactory attempts was recorded. *: Significant
difference (P <0.01) versus the indicated group, as determined by
t-test following a one-way ANOVA.
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at levels above Step 4, had more episode of acute ex-
acerbation within a year, had lower ACT scores, andwere more likely to have uncontrolled asthma than pa-
tients with a longitudinal decrease in IgE or no change
in IgE. In addition, more airway obstructions were ob-
served among patients with a longitudinal increase in
IgE. These results suggest that a longitudinal increase
in IgE is associated with poor asthma control. To our
knowledge, this is the first study to investigate the clin-
ical role of longitudinal change in total IgE in patients
with adult asthma and to demonstrate the possible associ-
ation between a longitudinal increase in IgE and poor
control of adult asthma. Recent global trials showed no
association between absolute IgE levels and asthma se-
verity in patients with adult asthma [13,14]. Consider-
ing these previous global trials, our interpretation of
the present study is that a measurement of longitudinal
change but not absolute value in total IgE predicts, to
some extent, asthma control in clinical practice.
Longitudinal changes in IgE vary considerably among
individual in patients with adult asthma, as shown in
Figure 1. We stratified adult asthma patients according
to the longitudinal change in IgE to identify characteris-
tics of patients with increased IgE. We found that the
mean age of patients with a longitudinal increase in IgE
was higher than that of patients with a decrease or no
change in IgE, suggesting that an increase in total IgE is
associated with aging among patients with uncontrolled
asthma. Previous epidemiological studies showed that
mean total IgE levels in patients with asthma decreased
with age [20,26]. The participants in these studies were
younger, (mostly less than 60) than those who enrolled
in our study. In addition, these studies were cross-
sectional rather than longitudinal. Thus, the results of
these studies cannot be easily compared with our data.
Further investigation of longitudinal changes in total and
antigen-specific IgE in adult asthma, particularly over
the age of 60, is needed.
Previous studies have shown that males and current
smokers have higher IgE levels than females and non-
current smokers, respectively [27-29]. In the current
study, there were no significant differences in gender or
current smoking status between three groups (Table 1).
The reasons for this are still unclear, but one possible
reason for the lack of a difference in smoking status is
that participants whose smoking history was greater
than 20 pack-years were excluded for exclusion of
COPD.
The total IgE level reflects both specific and unspe-
cific IgE. Matricardi et al. followed total and allergen-
specific IgE levels in children from birth to 13 years of
age [30]. This study revealed that the evolution of total
IgE was extremely heterogeneous but was parallel with
that of allergen-specific IgE from the age of 5 onwards.
Furthermore, Carsin et al. demonstrated that total IgE
level is related to new-onset asthma, but this association is
Table 2 Numbers and percentages of patients positive for antigen-specific IgE
HDM cedar ragwood candida Aspergillus* alter-naria dog dander cat dander moth cock-roach
decrease (N = 63) 42/63 (66.6%) 29/63 (46.0%) 5/63 (7.9%) 11/63 (17.4%) 4/63 (6.3%) 3/63 (4.7%) 11/47 (23.4%) 11/47 (23.4%) 13/50 (26.0%) 6/47 (12.7%)
no change (N = 50) 31/50 (62.0%) 32/50 (64.0%) 1/50 (2.0%) 8/50 (16.0%) 5/50 (10.0%) 1/50 (2.0%) 7/33 (21.2%) 8/33 (24.2%) 10/34 (29.4%) 4/22 (18.1%)
increase (N = 41) 22/41 (53.6%) 24/41 (58.5%) 6/41 (14.6%) 10/41 (24.3%) 15/41 (36.5) 5/41 (12.1%) 5/32 (15.6%) 5/32 (15.6%) 7/31 (22.5%) 6/29 (31.0%)
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present study, specific IgE to HDM was the most preva-
lent, followed by cedar-specific IgE. The prevalence of
specific IgE to HDM and cedar did not differ between
groups, indicating that these antigen-specific IgE did
not contribute to the longitudinal increase in total IgE.
The prevalence of specific IgE to fungi, such as asper-
gillus and alternaria, was higher in the increased IgE
group than in the other two other groups. In particular,
significant difference was observed for aspergillus-specific
IgE. This suggests that specific IgE to fungi, especially as-
pergillus, might have contributed to the longitudinal in-
crease in total IgE and also to poor control in the
increased IgE group. This is clinically plausible, since
sensitization to aspergillus is one of the factors that results
in difficult-to-treat asthma, such as allergic bronchopul-
monary aspergillosis (ABPA) and severe asthma with fun-
gal sensitization (SAFS) [32]. In addition, a previous study
showed that specific IgE to Aspergillus fumigatus con-
tributed to an increased risk of adult onset of asthma
[33]. To the best of our knowledge, this is the first re-
port indicating the association between aspergillus-
specific IgE and a longitudinal increase in total IgE in
patients with adult asthma.
There are several limitations to our study. First, al-
though we showed that patients with increased IgE had a
higher prevalence of aspergillus-specific IgE than pa-
tients with decreased or unchanged IgE, a longitudinal
change in aspergillus-specific IgE could not be shown.
Thus, to demonstrate directly the contribution of aspergil-
lus-specific IgE to the increase in total IgE and poor con-
trol of asthma, we should assesse the association between
longitudinal change in aspergillus-specific IgE and longitu-
dinal change in total IgE and control levels.
Second, the treatments of patients were not taken
into consideration in this study. The treatments of all
patients enrolled in this study have changed, usually a
number of times, during the past 10 years. Therefore,
we could not account for the treatments in our analysis.
It remains unclear how treatments affect longitudinal
changes in total IgE and antigen-specific IgE.
In conclusion, this is the first study to investigate the
clinical roles of longitudinal change in serum total IgE in
patients with asthma. We demonstrated that longitu-
dinal increase in total IgE is associated with poor asthma
control and a higher prevalence of aspergillus-specific
IgE in patients with adult asthma, suggesting a signifi-
cant contribution of IgE in the pathophysiology of severe
asthma. Further prospective analysis is needed to valid-
ate our data.
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